NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE445.85-3.85 (-0.86 %)
PREV CLOSE ( ) 449.70
OPEN PRICE ( ) 451.25
BID PRICE (QTY) 445.50 (25)
OFFER PRICE (QTY) 445.80 (8)
VOLUME 19719
TODAY'S LOW / HIGH ( )444.70 453.70
52 WK LOW / HIGH ( )299.3 470.9
NSE445.55-4.65 (-1.03 %)
PREV CLOSE( ) 450.20
OPEN PRICE ( ) 450.75
BID PRICE (QTY) 445.20 (124)
OFFER PRICE (QTY) 445.60 (268)
VOLUME 487659
TODAY'S LOW / HIGH( ) 444.70 454.00
52 WK LOW / HIGH ( )299.3 471
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 19-09 2005
Management Info
Malempati Venugopala Rao - Chairman - Managing Director
Registered Office

Address Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, Anakapalli,
Vishakhapatnam,
Andhra Pradesh-531021

Phone 0891 3061222 / 6601222

Email info@lauruslabs.com

Website www.lauruslabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE
NEWS
25Apr Appointment of Director
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Appointment of Chairman
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Resignation of Chairman
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Resignation of Director
Inter alia, approved:- 1. Approved the payment of 02nd interim dividen..
25Apr Laurus Labs reports 30% fall in Q4 con
Laurus Labs has reported results for fourth quarter (Q4) and year ended..
MORE
Financials
Rs. in Millions
QTR Mar 24 ANNUAL 24
Net Profit1213.22237
Gross Profit 1643.1 3014.7
Operating Profit 29527973
Net Sales 14145.248123.9
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Ajanta Pharma (BSE)
 2368.75 (6.07%)
M.Cap (Rs. in Cr)30085.03
Dr. Reddy's Lab (BSE)
 6359.75 (1.14%)
M.Cap (Rs. in Cr)105896.24
Torrent Pharma (BSE)
 2733.20 (2.22%)
M.Cap (Rs. in Cr)93581.86
Astrazeneca Pharma I (BSE)
 5386.65 (0.99%)
M.Cap (Rs. in Cr)13451.75
Alembic Pharma (BSE)
 1039.45 (4.65%)
M.Cap (Rs. in Cr)20251.90
MORE
Shareholding Pattern
NON-INSTITUTION 35.07%
PROMOTERS 27.19%
MUTUAL FUNDS/UTI 6.68%
FI/BANKS/INSURANCE 4.75%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.